Supernus Pharma Revenue, Profits - SUPN Annual Income Statement

Add to My Stocks
$44.05 $1.3 (2.87%) SUPN stock closing price Mar 21, 2018 (Closing)

Looking at financial statements, along with the Supernus Pharma stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $215M for 2016 impacts the SUPN stock. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses as shown in the Supernus Pharma profit and loss statement for 2016 total to $148.8M. This line item shows that the operating expenses has increased compared with last year. Also check: Supernus Pharma assets and Supernus Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2016201520142013201220112010
Supernus Pharma Revenues or Net Sales
Cost Of Goods Sold (COGS)11.98M8.42M5.75M1.1M---
Supernus Pharma Gross Profit
Research & Development Expense42.79M29.13M19.58M17.24M23.51M30.62M35.14M
Selling General & Admin Expense106.01M89.2M72.47M55.59M20.13M7.92M5.08M
Income Before Depreciation Depletion Amortization54.21M17.66M24.23M-61.92M-42.16M-37.75M-40.12M
Depreciation Depletion Amortization-------
Non Operating Income1.24M-1.46M--22.5M-0.54M--
Interest Expense5.09M1.22M4.96M7.84M3.57M1.86M-
Supernus Pharma Pretax Income
Provision for Income Taxes-40.85M-----16.24M-0.39M
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations91.22M14.01M19.87M-92.27M-46.28M-23.22M-39.07M
Extraordinary Items & Discontinued Operations-----77.04M-
Supernus Pharma Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS51.71M51.16M50.58M31.85M17.44M1.61M-
Average Shares used to compute Basic EPS49.47M47.49M42.26M31.85M17.44M1.61M-
Income Before Nonrecurring Items50.37M15.54M-10.35M-69.37M-47.43M-23.23M-
Income from Nonrecurring Items40.85M-1.52M30.22M-22.9M---
Supernus Pharma Earnings Per Share Basic Net
Supernus Pharma Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items0.950.31-0.24-2.18-2.72-16.60-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Supernus Pharma stock analysis. It helps to look at the following income statement items:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that SUPN stock has a topline or revenue of $215M for 2016 as per this Supernus Pharma revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $91.22M for Supernus Pharma for 2016. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the SUPN income statement, one can check the Supernus Pharma historical stock prices to check how the price has moved with time.

Supernus Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
PS Ratio (price sales ratio)
Operating Margin
Net Profit Margin
Dividend Yield